Brave Asset Management Inc. Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Brave Asset Management Inc. purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,000 shares of the company’s stock, valued at approximately $148,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Values First Advisors Inc. grew its holdings in shares of Recursion Pharmaceuticals by 11.6% during the fourth quarter. Values First Advisors Inc. now owns 59,205 shares of the company’s stock valued at $584,000 after purchasing an additional 6,140 shares during the last quarter. ARK Investment Management LLC boosted its stake in Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after purchasing an additional 13,777,689 shares in the last quarter. Interchange Capital Partners LLC bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $224,000. Exchange Traded Concepts LLC increased its stake in Recursion Pharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 16,359 shares of the company’s stock worth $161,000 after purchasing an additional 4,148 shares in the last quarter. Finally, Green Alpha Advisors LLC raised its position in Recursion Pharmaceuticals by 96.5% during the fourth quarter. Green Alpha Advisors LLC now owns 67,871 shares of the company’s stock valued at $669,000 after buying an additional 33,329 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Needham & Company LLC upped their target price on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, KeyCorp increased their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $12.75.

Insiders Place Their Bets

In related news, CEO Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total value of $445,067.84. Following the transaction, the chief executive officer now directly owns 774,703 shares of the company’s stock, valued at $7,142,761.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Christopher Gibson sold 48,272 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $9.22, for a total value of $445,067.84. Following the completion of the transaction, the chief executive officer now owns 774,703 shares of the company’s stock, valued at $7,142,761.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Tina Marriott Larson sold 8,000 shares of the company’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $10.35, for a total value of $82,800.00. Following the completion of the sale, the chief operating officer now owns 414,548 shares in the company, valued at approximately $4,290,571.80. The disclosure for this sale can be found here. Insiders have sold a total of 353,107 shares of company stock worth $3,856,834 in the last quarter. Corporate insiders own 19.96% of the company’s stock.

Recursion Pharmaceuticals Price Performance

RXRX traded down $0.20 during trading on Thursday, reaching $9.97. The company had a trading volume of 5,181,308 shares, compared to its average volume of 7,178,251. The business’s fifty day moving average price is $11.16 and its 200 day moving average price is $9.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.54 and a 12 month high of $16.75. The company has a market cap of $2.34 billion, a P/E ratio of -6.43 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.